Showing results (651-660 of 709) with videos related to
Sort By:
Pageof 71
Hepatology (Baltimore, Md.)|November 10, 2025
A multicenter dose-defining/expansion phase 1b study of first-line regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinomaAnthony B El-Khoueiry, Richard D Kim, William P Harris, et al.The Lancet. Infectious Diseases|March 26, 2013
Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trialKatja Deterding, Norbert Grüner, Peter Buggisch, et al.The Lancet. Oncology|May 30, 2021
Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trialPeter R Galle, Richard S Finn, Shukui Qin, et al.Hepatology (Baltimore, Md.)|June 10, 2008
Simplified criteria for the diagnosis of autoimmune hepatitisElke M Hennes, Mikio Zeniya, Albert J Czaja, et al.JCI Insight|August 10, 2021
Epigenetic modifications precede molecular alterations and drive human hepatocarcinogenesisCarolin Czauderna, Alicia Poplawski, Colm J O'Rourke, et al.Liver International : Official Journal of the International Association for the Study of the Liver|June 26, 2021
Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiologyPeter R Galle, Masatoshi Kudo, Josep M Llovet, et al.Journal of Hepatology|October 28, 2025
BCLC strategy for prognosis prediction and treatment recommendations: The 2025 updateMaria Reig, Marco Sanduzzi-Zamparelli, Alejandro Forner, et al.Liver International : Official Journal of the International Association for the Study of the Liver|April 13, 2020
Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2Masatoshi Kudo, Peter R Galle, Josep M Llovet, et al.Nature Medicine|May 10, 2000
Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivoR Atreya, J Mudter, S Finotto, et al.The New England Journal of Medicine|May 14, 2020
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular CarcinomaRichard S Finn, Shukui Qin, Masafumi Ikeda, et al.Pageof 71